BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hopkins, K.
Right arrow Articles by Kemshead, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hopkins, K.
Right arrow Articles by Kemshead, J. T.

The British Journal of Radiology, Vol 70, Issue 839 1152-1161, Copyright © 1997 by British Institute of Radiology

ARTICLES

A model to estimate the dose to tumour following intracavity administration of radioimmunoconjugates to patients with malignant gliomas

K Hopkins, V Papanastassiou, FA Zananiri and JT Kemshead
Paediatric & Neuro-Oncology Laboratories, University of Bristol, Frenchay NHS Healthcare Trust, UK.

Patients who have relapsed following primary treatment for malignant glioma and have undergone further surgical debulking have been treated with an anti-human neural cell adhesion molecule (NCAM) MoAb linked to either Iodine-131 or Yttrium-90. These reagents are introduced into the tumour resection cavity via an Ommaya reservoir. Pharmacokinetic and imaging studies indicate that the radioimmunoconjugate remains within the cavity for a protracted period of time. In this manuscript we develop a dosimetric model to predict the dose delivered to the rim of tissue surrounding the resection cavity. The model takes into account variables such as the diameter of the cavity and the degree of antibody binding which is achieved. Whilst the calculated doses to the wall of the cavity are relatively inaccurate due to our inability to measure factors such as diffusion and heterogeneity in antibody uptake, the model illustrates the potential benefits and pitfalls that can result from targeting the two radionuclides. It is hoped that as increasing interest is shown in this type of "liquid brachytherapy" other groups will find it useful to apply the model to allow comparisons to be made between our targeting strategy and those developed by other individuals.


This article has been cited by other articles:


Home page
 JNMHome page
M. Ferrari, M. Cremonesi, M. Bartolomei, L. Bodei, M. Chinol, M. Fiorenza, G. Tosi, and G. Paganelli
Dosimetric Model for Locoregional Treatments of Brain Tumors with 90Y-Conjugates: Clinical Application with 90Y-DOTATOC
J. Nucl. Med., January 1, 2006; 47(1): 105 - 112.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 1997 by the British Institute of Radiology.